ELI LILLY AND COMPANY Proceeds from Sale of Available-for-sale Securities, Equity
ELI LILLY AND COMPANY (LLY) reported Proceeds from Sale of Available-for-sale Securities, Equity of $951.50 million for the 3-month period ending 2017-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesEquity · last filed 2018-11-06
- ELI LILLY AND COMPANY proceeds from sale of available-for-sale securities, equity for the quarter ending 2017-09-30 was $951.50M.
- ELI LILLY AND COMPANY proceeds from sale of available-for-sale securities, equity for the quarter ending 2017-06-30 was $959.00M.
- ELI LILLY AND COMPANY proceeds from sale of available-for-sale securities, equity for the quarter ending 2017-03-31 was $1.09B.
| Period end | Proceeds from Sale of Available-for-sale Securities, Equity 3 month | Proceeds from Sale of Available-for-sale Securities, Equity 6 month | Proceeds from Sale of Available-for-sale Securities, Equity 9 month |
|---|---|---|---|
| 2017-09-30 | $951.50M 10-Q · filed 2018-11-06 | $1.91B derived: sum of 2 quarters · filed 2018-11-06 | $3.00B 10-Q · filed 2018-11-06 |
| 2017-06-30 | $959.00M 10-Q · filed 2018-07-25 | $2.05B 10-Q · filed 2018-07-25 | |
| 2017-03-31 | $1.09B 10-Q · filed 2018-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |